These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16315865)

  • 21. [Safety and efficacy of weekly paclitaxel followed by FEC100 as primary systemic therapy for breast cancer].
    Naito K; Oura S; Yoshimasu T; Tamaki T; Ohta F; Nakamura R; Shimizu Y; Kiyoi M; Hirai Y; Miyasaka M; Okamura Y
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):251-4. PubMed ID: 19223740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer.
    Lindman H; Aström G; Ahlgren J; Villman K; Blomqvist C; Nygren P; Bergh J
    Acta Oncol; 2007; 46(2):165-71. PubMed ID: 17453364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer.
    Biron P; Durand M; Roché H; Delozier T; Battista C; Fargeot P; Spaeth D; Bachelot T; Poiget E; Monnot F; Tanguy ML; Curé H
    Bone Marrow Transplant; 2008 Mar; 41(6):555-62. PubMed ID: 18037940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Side effects of FEC100].
    Endo A; Watanabe T; Kodama H; Shiga C; Kikuchi S; Yokota T
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):467-70. PubMed ID: 18347396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
    ; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
    J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
    Vulsteke C; Lambrechts D; Dieudonné A; Hatse S; Brouwers B; van Brussel T; Neven P; Belmans A; Schöffski P; Paridaens R; Wildiers H
    Ann Oncol; 2013 Jun; 24(6):1513-25. PubMed ID: 23396606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.
    Toledano A; Garaud P; Serin D; Fourquet A; Bosset JF; Breteau N; Body G; Azria D; Le Floch O; Calais G
    Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):324-32. PubMed ID: 16542788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prediction of response to primary systemic chemotherapy involving weekly paclitaxel followed by FEC 100 for advanced breast cancer].
    Higaki K; Ohtani S; Kin R; Masumura K; Harano M; Urashima M; Kagemoto M; Takada S; Matsuura H
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1513-7. PubMed ID: 18799903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Adjuvant epirubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study].
    Saimura M; Mitsuyama S; Anan K; Tanaka M; Shimada K; Hirose N; Ogawa S; Tamaki N; Tomisaki S; Tamura K
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1519-23. PubMed ID: 18799904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.
    Rocca A; Peruzzotti G; Ghisini R; Viale G; Veronesi P; Luini A; Intra M; Pietri E; Curigliano G; Giovanardi F; Maisonneuve P; Goldhirsch A; Colleoni M
    Anticancer Drugs; 2006 Nov; 17(10):1201-9. PubMed ID: 17075320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
    Fornier MN; Seidman AD; Lake D; D'Andrea G; Bromberg J; Robson M; Van Poznak C; Panageas KS; Atienza M; Norton L; Hudis C
    Clin Cancer Res; 2007 Jan; 13(1):223-7. PubMed ID: 17200358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early effects of 5-fluorouracil, epirubicin and cyclophosphamide therapy on common laboratory tests.
    Kailajärvi M; Ahokoski O; Virtanen A; Salminen E; Irjala K
    Anticancer Res; 2001; 21(4B):2867-72. PubMed ID: 11712778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
    Ardavanis A; Scorilas A; Tryfonopoulos D; Orphanos G; Missitzis I; Karamouzis M; Chrysochoou M; Sotiropoulou A; Arnogiannaki N; Ioannidis G; Pissakas G; Rigatos G
    Oncologist; 2006 Jun; 11(6):563-73. PubMed ID: 16794236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Predictive factors of nausea/vomiting of breast cancer patients receiving FEC and AC chemotherapy].
    Nomura H; Kawakami H; Nagai S; Shinohara T; Imoto S; Isaka H
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):941-6. PubMed ID: 18633221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.
    Baghi M; Hambek M; May A; Radeloff A; Gstoettner W; Knecht R
    Anticancer Res; 2006; 26(1B):559-63. PubMed ID: 16739320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line chemotherapy with fluorouracil-epirubicin-navelbine (FEN) combination in advanced breast cancer.
    Ardavanis A; Tryfonopoulos D; Orphanos G; Ioannidis G; Karamouzis M; Rigatos G
    Anticancer Res; 2005; 25(6C):4493-8. PubMed ID: 16334132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical hearing loss in women with breast cancer receiving adjuvant treatment.
    Jenkins V; Beveridge H; Low R; Mitra S
    Breast; 2006 Jun; 15(3):448-51. PubMed ID: 16135407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
    Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
    Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.